Dynamic sales activities with Iberoinvesa already initiated
European DCP phase completed / Launches in Europe’s most important markets within a year
Phase 1 study into the use of PVP hypericin in patients with bladder cancer
Increase in sales revenue / bottom line impacted by weak Q1 / cost-cutting programme yields positive Q3
Net result improves / earnings impacted by currency translation effects and higher spendings
Displaying results 1 to 5 out of 21
|
| |
